Does Remicade Cause Weight Gain in Crohn's Patients?
Remicade (infliximab), a TNF-alpha inhibitor used to treat Crohn's disease, does not list weight gain as a common side effect in its official labeling. Clinical trials and post-marketing data show most patients experience no significant weight changes, but some report modest gains, often tied to the drug's primary benefit: reducing inflammation and restoring appetite in underweight Crohn's patients.[1][2]
Why Might Some Crohn's Patients Gain Weight on Remicade?
Crohn's often causes weight loss from poor nutrient absorption, diarrhea, and suppressed appetite. Remicade controls flares, improves gut function, and boosts caloric intake, leading to weight gain in 10-20% of patients—typically 2-5 kg in the first year. This is intentional disease reversal, not a direct side effect. Studies like the ACCENT I trial noted average gains of 1-3 kg, highest in those underweight at baseline.[3][4]
How Common Is Weight Gain and Who Experiences It?
- Prevalence: Up to 18% in induction trials; less in maintenance (around 5-10%). More frequent in patients with baseline BMI under 20.[3]
- Patient factors: Younger adults, severe malnutrition history, or concurrent steroids increase odds. Women report it slightly more than men.[5]
- Real-world data from patient registries (e.g., TREAT) confirm gains stabilize after 6-12 months, with no long-term obesity risk.[2]
What Do Patients Report About Weight Gain?
Forums like Crohn's & Colitis Foundation communities and Drugs.com reviews show mixed experiences: many celebrate regaining lost weight ("finally eating normally"), while a minority (under 5%) complain of unwanted gain ("packed on 15 lbs despite diet"). No causal link to Remicade alone—often overlaps with reduced activity post-flare.[6]
Risks of Weight Gain on Remicade
Excess gain is rare but can worsen conditions like diabetes or joint stress in obese patients. Monitor BMI; physicians adjust doses or add diet counseling. No evidence of disproportionate fat gain vs. muscle.[1][4] Stopping Remicade usually halts related gains.
Alternatives to Remicade for Crohn's Treatment
| Drug | Weight Impact in Crohn's | Key Difference |
|------|---------------------------|---------------|
| Humira (adalimumab) | Similar; 10-15% gain from appetite recovery | Subcutaneous, fewer infusions |
| Stelara (ustekinumab) | Lower incidence (5-8%); less gut-focused | Targets IL-12/23, good for non-responders |
| Entyvio (vedolizumab) | Minimal weight change | Gut-selective, fewer systemic effects |
| Methotrexate/oral steroids | Variable; steroids notorious for gain | Cheaper but more side effects |
Switching reduces gain risk if Remicade controls symptoms.[7]
[1]: FDA Remicade Label
[2]: Lichtenstein GR, et al. Clin Gastroenterol Hepatol 2006 (TREAT registry)
[3]: Hanauer SB, et al. Gastroenterology 2002 (ACCENT I trial)
[4]: Colombel JF, et al. Gastroenterology 2010 (SONIC trial)
[5]: Hommes DW, et al. Gut 2009
[6]: Patient reviews aggregated from Drugs.com and CCFA.org
[7]: Singh S, et al. Am J Gastroenterol 2019 (meta-analysis)